Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ANRO Stock Forecast 2026-2027
$18.26
Current Price
$640.82M
Market Cap
Buy 11
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to ANRO Price Targets
+173.8%
To High Target of $50.00
+91.7%
To Median Target of $35.00
+31.4%
To Low Target of $24.00
ANRO Price Momentum
-9.0%
1 Week Change
-25.4%
1 Month Change
+610.5%
1 Year Change
+2.6%
Year-to-Date Change
-35.8%
From 52W High of $28.44
+749.3%
From 52W Low of $2.15
📊 TOP ANALYST CALLS
Did ANRO Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Alto Neuroscience is one of their latest high-conviction picks.
Latest ANRO Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, ANRO has a bullish consensus with a median price target of $35.00 (ranging from $24.00 to $50.00). The overall analyst rating is Strong Buy (9.7/10). Currently trading at $18.26, the median forecast implies a 91.7% upside. This outlook is supported by 11 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Patrick R. Trucchio at HC Wainwright & Co., projecting a 173.8% upside. Conversely, the most conservative target is provided by Laura Chico at Wedbush, suggesting a 31.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ANRO Analyst Ratings
11
Buy
1
Hold
0
Sell
ANRO Price Target Range
Low
$24.00
Average
$35.00
High
$50.00
Current: $18.26
Latest ANRO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ANRO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 18, 2026 | Baird | Brian Skorney | Outperform | Maintains | $36.00 |
| May 14, 2026 | Wedbush | Laura Chico | Neutral | Maintains | $24.00 |
| May 11, 2026 | HC Wainwright & Co. | Patrick R. Trucchio | Buy | Reiterates | $50.00 |
| Apr 22, 2026 | Chardan Capital | Buy | Maintains | $N/A | |
| Apr 2, 2026 | Baird | Outperform | Maintains | $N/A | |
| Apr 2, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Apr 2, 2026 | Jones Trading | Buy | Maintains | $N/A | |
| Apr 2, 2026 | Wedbush | Neutral | Maintains | $N/A | |
| Apr 2, 2026 | Chardan Capital | Buy | Maintains | $N/A | |
| Mar 18, 2026 | Baird | Outperform | Maintains | $N/A | |
| Mar 17, 2026 | Chardan Capital | Buy | Maintains | $N/A | |
| Mar 17, 2026 | Wedbush | Neutral | Maintains | $N/A | |
| Feb 17, 2026 | BTIG | Buy | Maintains | $N/A | |
| Jan 5, 2026 | Chardan Capital | Buy | Maintains | $N/A | |
| Nov 17, 2025 | BTIG | Buy | Initiates | $N/A | |
| Nov 13, 2025 | Baird | Outperform | Maintains | $N/A | |
| Nov 12, 2025 | Jefferies | Buy | Maintains | $N/A | |
| Oct 24, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Oct 20, 2025 | Baird | Outperform | Maintains | $N/A | |
| Sep 29, 2025 | Chardan Capital | Buy | Initiates | $N/A |
Alto Neuroscience Inc. (ANRO) Competitors
The following stocks are similar to Alto Neuroscience based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ANRO
Alto Neuroscience
mkt cap
704.34M
Alto Neuroscience Inc. (ANRO) Financial Data
Valuation Metrics
Market Cap
$640.82M
Enterprise Value
$419.67M
P/E Ratio
N/A
PEG Ratio
-5.5x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+41.2%
Current Ratio
20.5x
Debt/Equity
9.0x
ROE
-38.9%
ROA
-21.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Alto Neuroscience Inc. (ANRO) Business Model
About Alto Neuroscience Inc.
What They Do
Develops precision therapeutics for psychiatric disorders.
Business Model
The company generates revenue by creating tailored treatments for mental health conditions using advanced neurobiological insights and digital tools. By employing AI-driven patient profiling and biomarker-based approaches, Alto Neuroscience enhances treatment efficacy, offering a personalized alternative to traditional psychotropic medications.
Additional Information
Alto Neuroscience operates at the intersection of biotechnology and digital health, aiming to innovate psychiatric treatments. Their work not only seeks to improve patient outcomes but also aims to streamline the process of mental health medication management, reducing trial and error for patients.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
68
CEO
Dr. Amit Etkin M.D., Ph.D.
Country
United States
IPO Year
N/A
Website
www.altoneuroscience.comAlto Neuroscience Inc. (ANRO) Latest News & Analysis
Latest News
Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors
9 days ago
Quick Summary
Alto Neuroscience (NYSE: ANRO) appointed Andrew Miller, Ph.D. to its Board of Directors, effective May 27, 2026, as the company advances its development of precision medicines for neuropsychiatric disorders.
Why It Matters
The appointment of Andrew Miller, Ph.D. to Alto Neuroscience's Board signals potential strategic shifts or advancements, impacting the company's direction and future performance, relevant for stock valuation.
Source: Business Wire
Market Sentiment:
Neutral
Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award
22 days ago
Quick Summary
Alto Neuroscience (NYSE: ANRO) announced that CEO Amit Etkin received the Transformational Research Award from Columbia University for his contributions to neuropsychiatric disorder treatments.
Why It Matters
Alto Neuroscience's recognition of its CEO enhances its credibility and can boost investor confidence, potentially impacting stock performance positively in the biopharmaceutical sector.
Source: Business Wire
Market Sentiment:
Neutral
Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights
24 days ago
Quick Summary
Alto Neuroscience (NYSE: ANRO) reported Q1 2026 financial results and announced the start of a Phase 2b trial for its candidate ALTO-207, marking progress in its clinical pipeline.
Why It Matters
Alto Neuroscience's strong quarterly results and progress in clinical trials signal potential advancements in neuropsychiatric treatments, which could impact stock performance and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Alto Neuroscience, Inc. (NYSE: ANRO) will present at the Bank of America Securities Healthcare Conference from May 12-14, 2026, with a presentation on May 1.
Why It Matters
Alto Neuroscience's participation in major investor conferences can enhance visibility, attract potential investors, and signal confidence in its developmental pipeline, influencing stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting
1 month ago
Quick Summary
Alto Neuroscience (NYSE: ANRO) presented data from a Phase 2a trial of ALTO-207 for Major Depressive Disorder at the 2026 SOBP meeting.
Why It Matters
Positive trial results for ALTO-207 in treating Major Depressive Disorder could enhance Alto Neuroscience's market position, attract investment, and influence stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression
1 month ago
Quick Summary
Alto Neuroscience (NYSE: ANRO) has begun a Phase 2b trial for ALTO-207 in treatment-resistant depression, aiming to replicate positive PAX-D study results and facilitate registration.
Why It Matters
Alto Neuroscience's Phase 2b trial for ALTO-207 in treatment-resistant depression could validate previous positive results, potentially boosting stock value and market confidence in the company.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About ANRO Stock
What is Alto Neuroscience Inc.'s (ANRO) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, Alto Neuroscience Inc. (ANRO) has a median price target of $35.00. The highest price target is $50.00 and the lowest is $24.00.
Is ANRO stock a good investment in 2026?
According to current analyst ratings, ANRO has 11 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $18.26. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ANRO stock?
Wall Street analysts predict ANRO stock could reach $35.00 in the next 12 months. This represents a 91.7% increase from the current price of $18.26. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Alto Neuroscience Inc.'s business model?
The company generates revenue by creating tailored treatments for mental health conditions using advanced neurobiological insights and digital tools. By employing AI-driven patient profiling and biomarker-based approaches, Alto Neuroscience enhances treatment efficacy, offering a personalized alternative to traditional psychotropic medications.
What is the highest forecasted price for ANRO Alto Neuroscience Inc.?
The highest price target for ANRO is $50.00 from Patrick R. Trucchio at HC Wainwright & Co., which represents a 173.8% increase from the current price of $18.26.
What is the lowest forecasted price for ANRO Alto Neuroscience Inc.?
The lowest price target for ANRO is $24.00 from Laura Chico at Wedbush, which represents a 31.4% increase from the current price of $18.26.
What is the overall ANRO consensus from analysts for Alto Neuroscience Inc.?
The overall analyst consensus for ANRO is bullish. Out of 4 Wall Street analysts, 11 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $35.00.
How accurate are ANRO stock price projections?
Stock price projections, including those for Alto Neuroscience Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 6, 2026 2:07 AM UTC